
Home » Pipeline
Pipeline
Company | Drug/Device | Medical Condition | Status |
---|---|---|---|
Pfizer, Inc. | PF-06939926 | Duchenne muscular dystrophy (DMD) | Phase Ib trial initiated |
Synlogic | SYNB1618 | Phenylketonuria (PKU) | Phase I/IIa trial initiated |
NovoCure Ltd. | STELLAR | mesothelioma | Phase II top-line results announced evaluating 80 subjects |
Fervent Pharmaceuticals | FP-101 | vasomotor symptoms | Phase IIa trials initiated enrolling 112 subjects from across the southeastern U.S. |
Janssen Pharmaceutical Companies of Johnson & Johnson | esketamine | major depressive disorder at imminent risk for suicide | Phase IIa results announced evaluating 68 subjects |
Glenmark Pharmaceuticals | GBR 830 | moderate-to-severe atopic dermatitis | Phase IIb trials initiated enrolling 392 subjects |
Amgen | Aimovig (erenumab) | migraine | Phase IIIb final results announced evaluating 246 subjects |
Genentech, Inc. | HEMLIBRA (emicizumab-kxwh) | hemophilia A without factor VIII | Breakthrough Therapy Designation granted by the FDA |
King-Devick technologies, inc. | K-D Balance | conditions that could affect balance | 510(k) clearance granted by the FDA |
Alkermes | ALKS 54641 | major depressive disorder | NDA filed with the FDA |
NeuroVive Pharmaceutical AB | KL1333 | inherited mitochondrial respiratory chain diseases (MRCD) | Orphan Drug Designation granted by the FDA |
Boehringer Ingelheim Pharmaceuticals, Inc. | Praxbind (idarucizumab) | patients treated with Pradaxa when reversal of the anticoagulant effects of dabigatran is needed for emergency surgery/urgent procedures or in life-threatening or uncontrolled bleeding | FDA approved |
Upcoming Events
-
16Feb
-
21May